SI1603513T1 - Sestavki dantrolena - Google Patents

Sestavki dantrolena

Info

Publication number
SI1603513T1
SI1603513T1 SI200432506T SI200432506T SI1603513T1 SI 1603513 T1 SI1603513 T1 SI 1603513T1 SI 200432506 T SI200432506 T SI 200432506T SI 200432506 T SI200432506 T SI 200432506T SI 1603513 T1 SI1603513 T1 SI 1603513T1
Authority
SI
Slovenia
Prior art keywords
dantrolene
compositions
dantrolene compositions
Prior art date
Application number
SI200432506T
Other languages
English (en)
Inventor
David Anderson
Benjamin G. Cameransi
Vincent M. Conklin
Original Assignee
Lyotropic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyotropic Therapeutics, Inc. filed Critical Lyotropic Therapeutics, Inc.
Publication of SI1603513T1 publication Critical patent/SI1603513T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200432506T 2003-03-04 2004-03-01 Sestavki dantrolena SI1603513T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45124903P 2003-03-04 2003-03-04
US53932404P 2004-01-28 2004-01-28
EP04775816.4A EP1603513B1 (en) 2003-03-04 2004-03-01 Dantrolene compositions
PCT/US2004/006135 WO2005013919A2 (en) 2003-03-04 2004-03-01 Treatment using dantrolene

Publications (1)

Publication Number Publication Date
SI1603513T1 true SI1603513T1 (sl) 2021-04-30

Family

ID=34138425

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432506T SI1603513T1 (sl) 2003-03-04 2004-03-01 Sestavki dantrolena

Country Status (7)

Country Link
EP (1) EP1603513B1 (sl)
JP (1) JP4880449B2 (sl)
AU (1) AU2004262507B2 (sl)
CA (1) CA2516667C (sl)
ES (1) ES2862337T3 (sl)
SI (1) SI1603513T1 (sl)
WO (1) WO2005013919A2 (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2583670A1 (en) * 2007-10-09 2013-04-24 US Worldmeds LLC Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
WO2009067175A2 (en) * 2007-11-16 2009-05-28 Nektar Therapeutics Al, Corporation Oligomer-dantrolene conjugates and related compounds
US20120040970A1 (en) * 2009-04-27 2012-02-16 Al-Ghananeem Abeer M Intranasal delivery system for dantrolene
CN102293749B (zh) * 2011-06-30 2012-08-22 上海中医药大学附属普陀医院 一种马钱子碱免疫纳米微粒
MA50080A (fr) * 2017-09-05 2020-07-15 Eagle Pharmaceuticals Inc Méthodes d'utilisation du dantrolène pour traiter l'exposition à un agent neurotoxique
SG11202011121UA (en) * 2018-05-21 2020-12-30 Eagle Pharmaceuticals Inc Dantrolene formulations and methods of their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5320413B1 (sl) 1969-01-25 1978-06-27
JPS5822011B2 (ja) * 1976-08-10 1983-05-06 山之内製薬株式会社 安定なダントロレンナトリウムの製剤
US4137402A (en) * 1978-03-30 1979-01-30 Morton-Norwich Products, Inc. Quaternary ammonium salts of dantrolene and clodanolene
US4543359A (en) 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
WO1994005287A1 (en) 1992-09-09 1994-03-17 Washington University Prevention or treatment of sepsis with dantrolene or azumolene
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5728728A (en) 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
PT942780E (pt) 1997-09-09 2003-11-28 Lyotropic Therapeutics Inc Particulas revestidas processos de obtencao e uso
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001041756A2 (en) 1999-12-02 2001-06-14 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ZA200108038B (en) 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
CA2428993C (en) 2000-11-29 2011-05-31 Lyotropic Therapeutics, Inc. Solvent systems for pharmaceutical agents
US20030045587A1 (en) * 2001-06-23 2003-03-06 David Anderson Solvent system
US6921775B2 (en) 2001-08-03 2005-07-26 Children's Medical Center Corporation Methods for modulating brain damage
US8557855B2 (en) 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury

Also Published As

Publication number Publication date
CA2516667A1 (en) 2005-02-17
ES2862337T3 (es) 2021-10-07
AU2004262507B2 (en) 2010-02-18
WO2005013919A2 (en) 2005-02-17
AU2004262507A1 (en) 2005-02-17
JP2007525439A (ja) 2007-09-06
JP4880449B2 (ja) 2012-02-22
EP1603513A4 (en) 2009-09-30
EP1603513B1 (en) 2020-12-30
EP1603513A2 (en) 2005-12-14
CA2516667C (en) 2012-05-29
WO2005013919A3 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
GB0305941D0 (en) Composition
GB0302738D0 (en) Composition
GB0324918D0 (en) Composition
GB0329907D0 (en) Compositions
EP1613352A4 (en) MICRO-AGREED COMPOSITIONS
GB0324897D0 (en) Composition
GB0329597D0 (en) Compositions
HK1087034A1 (en) Actacid composition
GB0322033D0 (en) Composition
MY145151A (en) Composition
SI1603513T1 (sl) Sestavki dantrolena
GB0300602D0 (en) Compositions
GB0324574D0 (en) Novel compositions
GB0328023D0 (en) Novel compositions
GB0309317D0 (en) Composition
GB0316857D0 (en) Compositions
GB0324295D0 (en) Composition
GB0306312D0 (en) Composition
GB0326815D0 (en) Composition
GB0301869D0 (en) Composition
GB0322117D0 (en) Arthropodicdal compositions
GB0310479D0 (en) Compositions
GB0325537D0 (en) Compositions
GB0319649D0 (en) Compositions
GB0310480D0 (en) Compositions